Russian envoy says cooperation in countering COVID-19 priority area of bilateral partnership
Dec 01, 2020
New Delhi [India], December 2 : After phase 2/3 clinical trials for Sputnik V commenced in India on Tuesday, Russian Ambassador Nikolay Kudashev said comprehensive cooperation in countering the spread of coronavirus is a priority area of the Russia-India bilateral and multilateral strategic partnership.
"Comprehensive cooperation in countering the spread of novel coronavirus infection is a priority area of the Russia India bilateral and multilateral strategic partnership. Ready to continue every interaction and coordination in this area to support global efforts to combat COVID-19," Nikolay Kudashev tweeted.
Russian Direct Investment Fund (RDIF) and Dr Reddy's Laboratories on Tuesday said they have commenced adaptive Phase 2/3 clinical trials for the vaccine.
Russia became the first country to register the world's first Covid-19 vaccine on August 11. Sputnik V was developed by the Gamaleya National Research Centre for Epidemiology and Microbiology of the Russian Healthcare Ministry.
The Sputnik V vaccine is based on a well-studied human adenoviral vector platform that had proven safe and effective with no long-term side effects in more than 250 clinical trials globally conducted during the past two decades (while the history of use of human adenoviruses in vaccine development started in 1953). More than 100,000 people have received approved and registered drugs based on the human adenoviral vectors.
Last month, Russia said that its vaccine Sputnik V is 92 per cent effective at protecting people from COVID-19 according to the first interim analysis.
"The Sputnik V vaccine efficacy amounted to 92 per cent (calculation based on the 20 confirmed Covid-19 cases split between vaccinated individuals and those who received the placebo)," the RDIF said in a statement read.
Sputnik V vaccine against Covid-19 will be tested in India on 100 volunteers, the Indian Central Drugs Standard Control Organisation's Drug Controller General (DCGI) told Sputnik in October.
DCGI has granted permission to pharmaceutical giant Dr Reddy's Laboratories for conducting tests.
